Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Azurrx Biopharma Inc (AZRX)

Azurrx Biopharma Inc (AZRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,716
  • Shares Outstanding, K 93,262
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,670 K
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.88
Trade AZRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.92
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +64.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5381 +4.79%
on 07/23/21
0.8200 -31.23%
on 07/08/21
-0.2360 (-29.50%)
since 07/02/21
3-Month
0.5381 +4.79%
on 07/23/21
0.9700 -41.87%
on 06/07/21
-0.3510 (-38.36%)
since 04/30/21
52-Week
0.5381 +4.79%
on 07/23/21
2.6300 -78.56%
on 01/22/21
-0.4057 (-41.84%)
since 07/31/20

Most Recent Stories

More News
AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option to Purchase Additional Shares

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

"RESERVOIR" trial to evaluate niclosamide's ability to target SARS-CoV-2 in the GI tract

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
FMW Media's "New To The Street" Syndicated TV Show Features AzurRx BioPharma, Inc.

FMW Media Corp. announces that its "New To The Street" business TV show will feature AzurRx BioPharma, Inc. (NASDAQ: AZRX) in a 3-part TV series featured across its entire syndicated linear television...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

AzurRx BioPharma, Inc. (NASDAQ: AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

AZRX : 0.5612 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic...

See More

Key Turning Points

3rd Resistance Point 0.5727
2nd Resistance Point 0.5657
1st Resistance Point 0.5547
Last Price 0.5612
1st Support Level 0.5367
2nd Support Level 0.5297
3rd Support Level 0.5187

See More

52-Week High 2.6300
Fibonacci 61.8% 1.8309
Fibonacci 50% 1.5841
Fibonacci 38.2% 1.3372
Last Price 0.5612
52-Week Low 0.5381

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar